Watchlist: 5 Potential Catalysts Put (Nasdaq: ONCY) On Our Radar (Multiple Analyst Targets)

Advances in cancer therapy are accelerating, reshaping how the disease is treated.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Watchlist: 5 Potential Catalysts Put (Nasdaq: ONCY) On Our Radar (Multiple Analyst Targets) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* July 13th Greetings, Friend! Advances in cancer therapy are accelerating, reshaping how the disease is treated. This momentum stems from mounting pressure to deliver treatments that achieve better outcomes for patients. Against this backdrop, the gastrointestinal cancer market is expanding sharply, rising from $27.05Bn in 2025 to $30.33Bn in 2026. Still flying under-the-radar at this moment, one clinical-stage biotech firm has begun to draw attention for its distinct strategy. The strategy centers on immune-based approaches to address tumors that have proven difficult to treat. Rather than broadly targeting cells, its work emphasizes precision, aiming to attack cancer while leaving healthy tissue largely unaffected, placing it squarely in an area where treatment options remain limited. This momentum highlights a larger transformation underway in how cancer treatment could evolve in the coming years. And with an average analyst target pointing to the potential for triple-digit upside, this Nasdaq profile is now on our radar: Oncolytics Biotech Inc. (Nasdaq: ONCY) Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent.  Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. Pelareorep is a first-in-class, nonpathogenic, oncolytic virus that can be delivered intravenously and works by generating, recruiting, and training immune cells to recognize and kill cancer while remodeling the tumor microenvironment to enable immune cell access.  In addition to its demonstrated single-agent activity, pelareorep can also work in synergy with chemotherapy, immune checkpoint inhibitors (ICIs), CAR T-cell therapy, proteasome inhibitors, bispecific antibodies, and CDK4/6 and PARP inhibitors to enhance its antitumor potential and meaningfully extend patient remissions. Pelareorep specifically targets cancer cells and induces a cascade of inflammatory responses that activate the innate and adaptive immune system to destroy the tumor while sparing normal tissue. Pelareorep’s unique ability to introduce double-stranded RNA, a powerful immune stimulant, directly into cancer cells results in PD-L1 upregulation and cytokine and chemokine production, inducing enhanced infiltration and T-cell activation. Because pelareorep replicates only in tumor cells, it is well-tolerated by patients. Pelareorep Proposed Mechanism Of Action Oncolytics' Pipeline The cancer-fighting potential of pelareorep has generated partnerships with leading academic institutions and pharmaceutical industry collaborators. Given the validity of the mechanism of action and the efficacy observed thus far, the Company anticipates that its benefits will extend across multiple indications, including breast, gastrointestinal (GI), and hematologic malignancies. Discover Sources And More Here: ONCY Website. ONCY Presentation. ----- 5 Potential Catalysts Hit Our Radar For Monday - (Nasdaq: ONCY) 1.) An Average Analyst Target May Be Signaling That ONCY Is Undervalued From Its Current Chart Positioning. Take a look at this info found over at MarketBeat: From Friday's close, the average target of $8.50 that 4 analysts are projecting signal a potential upside of 800+%. From current chart levels, do these targets suggest (Nasdaq: ONCY) is underappreciated? 2.) Another Analyst Target Also Spells Triple-Digit Potential Upside For ONCY. In May, David Bautz of Zacks Small-Cap Research pegged a $6.00 target on ONCY. From its closing valuation on Friday, this target suggests ONCY may have a potential 550+% upside. 3.) Commercial-Scale Patent Extends Pelareorep Value, Strengthening Oncolytics’ Long-Term Growth Strategy. Oncolytics’ new U.S. patent is a meaningful win because it protects pelareorep’s manufacturing process through 2044 and supports reliable commercial-scale production.  The filing also adds to a broader intellectual property strategy that includes a pending method-of-use application expected to extend protection to 2046, with more patent filings planned in 2026. Together, these steps strengthen the company’s competitive moat, improve the asset’s long-term value, and reinforce confidence in pelareorep’s path toward registration and commercialization. 4.) Promising Preclinical Data Expands Pelareorep’s Cancer Killing Potential. Oncolytics reported encouraging preclinical results showing pelareorep produced stronger anti-tumor activity when combined with RAS-targeted agents than either approach alone. That matters because RAS-mutated cancers, especially pancreatic and colorectal tumors, remain hard to treat and often develop resistance, creating a large unmet need.  The company’s planned follow-on studies in PDAC and CRC, plus work with KRAS G12C and pan-RAS inhibitors, position pelareorep as a potentially valuable immune-priming backbone for next-generation combination therapies. 5.) Strategic Leadership Advancing Oncolytics Biotech Growth And Immunotherapy Platform. Oncolytics strengthened its leadership team by appointing Steve Glover to the Board of Directors and promoting John McAdory to Chief Operating Officer, supporting its growth strategy and pelareorep-focused immunotherapy platform. Glover’s track record, including leading Ambrx Biopharma through a ~$2Bn acquisition by Johnson & Johnson, enhances Oncolytics’ strategic and transactional expertise. McAdory will oversee clinical operations, R&D, and partnerships, helping accelerate development of pelareorep and broader immunotherapy initiatives, with particular momentum in gastrointestinal cancer indications. ----- Coverage has now begun on Oncolytics Biotech Inc. (Nasdaq: ONCY). Keep your eyes peeled for updates coming down the pipe shortly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/12/2026 and ending on 07/13/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty two thousand five hundred USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US). Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ONCY:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/oncy-rzcki/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice